PreveCeutical Medical Inc. (PREV.CN)
| Previous close | 0.0150 |
| Open | 0.0200 |
| Bid | 0.0200 x 0 |
| Ask | 0.0250 x 0 |
| Day's range | 0.0200 - 0.0250 |
| 52-week range | 0.0150 - 0.0300 |
| Volume | |
| Avg. volume | 220,207 |
| Market cap | 13.383M |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswirePREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM
PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that it has started preparations to accelerate completion of its preclinical dual gene therapy program using our developed and in vitro validated Smart-siRNA sequences, which when paired with our proprietary bioresponsive lipid-nanoparticulate delivery systems (US patent no. 11,566,044) effectively target the PTPN1 gene.
GlobeNewswireNew to The Street Announces its Five Corporate Interviews, airings on Newsmax and FOX Business Network
Broadcastings Begin Saturday, September 23, 2023, at 3:30 PM ET New to The Street Announces its Five Corporate Interviews, airings on Newsmax and FOX Business Network Shows 512/513: 1). American Rebel Holdings, Inc. (NASDAQ: AREB) ($AREB) 2). Society Pass Incorporated (NASDAQ: SOPA) ($SOPA) 3). PreveCeutical Medical, Inc. (OTCQB: PRVCF) (CSE: PREV) (FSE: 18H) 4). Artist – Hope Tain Oil Painting 5). Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®) - https://www.ne
PR NewswirePreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application
PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is proud to announce that Endosane Pharmaceuticals GmbH will proceed with its research initiative focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of CBD can be achieved with this technology. The company's commitment to advancing medical research is demonstrated through its comprehensive resea
